CN111012736A - 一种阻断新型冠状病毒2019-nCov的无菌喷剂敷料的应用 - Google Patents
一种阻断新型冠状病毒2019-nCov的无菌喷剂敷料的应用 Download PDFInfo
- Publication number
- CN111012736A CN111012736A CN202010086854.1A CN202010086854A CN111012736A CN 111012736 A CN111012736 A CN 111012736A CN 202010086854 A CN202010086854 A CN 202010086854A CN 111012736 A CN111012736 A CN 111012736A
- Authority
- CN
- China
- Prior art keywords
- spray dressing
- lht
- sterile spray
- bioactive peptide
- sterile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007921 spray Substances 0.000 title claims abstract description 53
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 27
- 230000000903 blocking effect Effects 0.000 title claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 40
- 230000000975 bioactive effect Effects 0.000 claims abstract description 38
- 241000700605 Viruses Species 0.000 claims abstract description 18
- 210000003928 nasal cavity Anatomy 0.000 claims abstract description 16
- 210000000214 mouth Anatomy 0.000 claims abstract description 15
- 239000011241 protective layer Substances 0.000 claims abstract description 8
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 6
- 210000001339 epidermal cell Anatomy 0.000 claims abstract description 6
- 210000005260 human cell Anatomy 0.000 claims abstract description 6
- 239000012528 membrane Substances 0.000 claims abstract description 6
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims abstract description 5
- 101710085938 Matrix protein Proteins 0.000 claims abstract description 5
- 101710127721 Membrane protein Proteins 0.000 claims abstract description 5
- 210000000234 capsid Anatomy 0.000 claims abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 241000003595 Aurantiochytrium limacinum Species 0.000 claims description 5
- 241000283074 Equus asinus Species 0.000 claims description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 102000004506 Blood Proteins Human genes 0.000 claims description 4
- 108010017384 Blood Proteins Proteins 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 4
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 108090000565 Capsid Proteins Proteins 0.000 claims description 3
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- -1 alanine (Ala) Chemical class 0.000 claims 1
- 239000002075 main ingredient Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 3
- 241001678559 COVID-19 virus Species 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 241000233671 Schizochytrium Species 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000009351 contact transmission Effects 0.000 description 2
- 230000009365 direct transmission Effects 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 1
- 101800000535 3C-like proteinase Proteins 0.000 description 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710114810 Glycoprotein Proteins 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种无菌喷剂敷料的应用,具体涉及一种阻断新型冠状病毒2019‑nCov的无菌喷剂敷料的应用。该无菌喷剂敷料主要成分生物活性肽LHT喷入到鼻腔或者口腔后,形成一道保护层,当病毒接触到鼻腔或者口腔的这层保护层后,生物活性肽LHT迅速和病毒的衣壳M蛋白质结合,使得其在未接触人体细胞之前就被挡在体外。另一方面,无菌喷剂敷料主要成分生物活性肽LHT喷入到鼻腔或者口腔后,也可与人体表皮细胞膜上的血管紧张素转换酶ACE及ACE2蛋白酶裸露外部的部位结合,使得新型冠状病毒入侵细胞的途径被阻断。
Description
技术领域
本发明涉及一种无菌喷剂敷料的应用,具体涉及一种阻断新型冠状病毒2019-nCov的无菌喷剂敷料的应用。
背景技术
2019新型冠状病毒(2019-nCoV),2020年1月12日被世界卫生组织命名。冠状病毒在***分类上属冠状病毒科(Coronaviridae)冠状病毒属(Coronavirus)。冠状病毒属的病毒是具包膜结构的正链单股RNA病毒,包膜结构上有三种蛋白:刺突糖蛋白(S,SpikeProtein)、小包膜糖蛋白(E,Envelope Protein)和膜糖蛋白(M,Membrane Protein)。S蛋白在识别并结合宿主细胞表面受体,并介导病毒包膜与细胞膜融合;M蛋白则参与了病毒包膜的形成与出芽过程。有研究表明,新型冠状病毒是通过自身的S蛋白识别人体支气管上皮细胞和肺泡细胞的细胞膜上的血管紧张素转换酶ACE及ACE2蛋白酶结合入侵人体,而感染肺炎的。2019新型冠状病毒是目前已知的第7种可以感染人的冠状病毒,其余6种分别是HCoV-229E、HCoV-OC43、HCoV-NL63、HCoV-HKU1、SARS-CoV和MERS-CoV。
人感染了2019新型冠状病毒之后,会引起一种急性感染性肺炎,患者初始症状多为发热、乏力和干咳,并逐渐出现呼吸困难等严重表现。多数患者预后良好,部分严重病例可出现急性呼吸窘迫综合征或脓毒症休克,甚至死亡。2019新型冠状病毒所致肺炎,传染性强,基于目前的流行病学调查,潜伏期多为1-14天,有少数感染者潜伏期会超过14天,潜伏期具有传染性,无症状感染者也可能成为传染源。目前可以确定的2019新型冠状病毒传播途径主要为直接传播、气溶胶传播和接触传播。直接传播是指患者喷嚏、咳嗽、说话的飞沫,呼出的气体近距离直接吸入导致的感染;气溶胶传播是指飞沫混合在空气中,形成气溶胶,吸入后导致感染;接触传播是指飞沫沉积在物品表面,接触污染手后,再接触口腔、鼻腔、眼睛等粘膜,导致感染。然而,目前能安全有效阻断新型冠状病毒感染的医疗产品和药品十分有限。
发明内容
为弥补上述不足,本发明旨在提供了一种阻断新型冠状病毒2019-nCov的无菌喷剂敷料的应用。该无菌喷剂敷料喷入到鼻腔或者口腔,形成一道保护层,屏障外界物质如病毒的侵入,且无毒副作用,安全可靠。
本发明是一种阻断新型冠状病毒2019-nCov的无菌喷剂敷料的应用,解决其技术问题所采用的技术方案包括以下内容:
所述无菌喷剂敷料含有生物活性肽LHT和辅料,其中,生物活性肽LHT添加量 0.1%-0.5%,辅料含有增稠剂0.1%-1%,防腐剂0.01%-0.5%,柠檬酸0.01%-0.2%,氯化钠0.3%-0.9%、磷酸氢二钠0.1%-1.5%,乙二胺四乙酸二钠0.01%-0.06%,纯化水定容至100%。
所述增稠剂优选羟乙基纤维素、羧甲基纤维素钠中的一种。
所述防腐剂优选羟苯甲酯、羟苯甲酯钠、羟苯乙酯中的一种或几种。
所述无菌喷剂敷料的应用,其特征在于,所述无菌喷剂敷料所含的生物活性肽LHT来源于海洋微藻裂殖壶菌酶解活性肽及驴血清蛋白质酶解混合物。
所述来源于海洋的微藻裂殖壶菌的活性肽是由来源于海洋微藻裂殖壶菌发酵后提取DHA后的藻粕,经过蛋白酶降解再分离纯化获得的,并且能与冠状病毒的衣壳M蛋白质结合,使得其在未接触人体细胞之前就被挡在体外,阻断其进入人体。
所述微藻裂殖壶菌是中华人民共和国*** (2010年第3号) 批准为新食品原材料,采用国际领先的生物信息学技术,靶向定位分离活性肽LHT,用于生产无菌喷剂敷料的主要原材料,其安全、无毒及可靠性已经由国家权威部门所证实。
所述驴血清白蛋白,已有研究表明,驴血清蛋白质酶解获得的肽对血管紧张素转换酶具有抑制作用,能与人体表皮细胞膜上的血管紧张素转换酶ACE及ACE2蛋白酶裸露外部的部位结合,使得新型冠状病毒入侵细胞的途径被阻断。
另外,所述的无菌喷剂敷料中的乙二胺四乙酸二钠,有研究表明,也具有阻断冠状病毒的作用。
本发明还提供了一种阻断新型冠状病毒2019-nCov的无菌喷剂敷料的应用。
所述无菌喷剂敷料的应用,其特征在于,所述无菌喷剂敷料所含的生物活性肽LHT的含有的氨基酸有丙氨酸(Ala),精氨酸(Arg),天门冬氨酸(Asp),谷氨酸(Glu),甘氨酸(Gly),组氨酸(His),异亮氨酸(Ile),亮氨酸(Leu),赖氨酸(Lys),脯氨酸(Pro),丝氨酸(Ser),苏氨酸(Thr),色氨酸(Trp),酪氨酸(Tyr),缬氨酸(Val),天门冬酰胺(Asn),半胱氨酸(Cys)。
所述无菌喷剂敷料的应用,其特征在于,所述无菌喷剂敷料所含的生物活性肽LHT的含有生物活性肽的分子式为 C43H76N10O18,C29H47N6O9,C33H60N7O9,C28H49N6O8S。
所述无菌喷剂敷料应用于II、III 类医疗器械产品。
所述无菌喷剂敷料用于口腔或鼻腔。
所述无菌喷剂敷料的生物活性肽LHT来源于海洋微藻裂殖壶菌酶解活性肽及驴血清蛋白质酶解混合物具有良好的协同作用,能够从两个方面阻断病毒入侵人体:
一方面:生物活性肽LHT与病毒衣壳蛋白质Mpro结合,对人体起到屏障作用:
含有生物活性肽LHT的无菌喷剂敷料,喷入到鼻腔或者口腔后,形成一道保护层,当病毒接触到鼻腔或者口腔的这层保护层后,生物活性肽LHT迅速和病毒的衣壳M蛋白质结合,使得其在未接触人体细胞之前就被挡在体外。该保护层起到屏障病毒的作用,阻断其进入人体。
另一方面:生物活性肽LHT能与病毒衣壳蛋白质竞争结合人体表皮细胞膜外的蛋白质阻断病毒入侵人体细胞的途径,对人体起到屏障作用:
含有生物活性肽LHT的无菌喷剂敷料,喷入到鼻腔或者口腔后,亦可与人体表皮细胞膜上的血管紧张素转换酶ACE及ACE2蛋白酶裸露外部的部位结合,使得新型冠状病毒入侵细胞的途径被阻断。即通过该无菌喷剂敷料与人体细胞外部共同形成一道屏障,阻断新型冠状病毒侵入人体。
具体实施方式
为了使得本领域技术人员能够更加清楚地了解本发明的技术方案,以下将结合具
体的实施例详细说明本发明的技术方案。
实施例1
生物活性肽LHT 0.18%,羧甲基纤维素钠0.3%,羟苯甲酯钠0.02%,柠檬酸0.12%,氯化钠0.48%、磷酸氢二钠1.4%,乙二胺四乙酸二钠0.05%,纯化水定容至100%。
实施例2
生物活性肽LHT 0.18%,羧甲基纤维素钠0.3%,羟苯甲酯钠0.02%,柠檬酸0.12%,氯化钠0.48%、磷酸氢二钠0.14%,乙二胺四乙酸二钠0.05%,纯化水定容至100%。
实施例3
生物活性肽LHT 0.18%,羟乙基纤维素0.3%,羟苯甲酯钠0.02%,柠檬酸0.12%,氯化钠0.48%、磷酸氢二钠0.14%,乙二胺四乙酸二钠0.05%,纯化水定容至100%。
实施例4 无菌喷剂敷料体验感调查
招募30名志愿者,每名志愿者将实施例1、实施例2、实施例3所制得的无菌喷剂敷料,分别喷于口腔和鼻腔进行感官评价,具体体验效果如下:实施例1-3所制得的无菌喷剂敷料30名志愿者均感觉有淡淡的咸味,其中,有1名志愿者感觉实施例1和实施例2的无菌喷剂敷料喷于鼻腔内有敏感、刺激的表现,实施例3的无菌喷剂敷料30名志愿者喷于口腔和鼻腔均无敏感、刺激的表现。
以上所描述的实施例方案并非是本发明全部的实施例方案,对于实施例方案的详细描述,并非是要求限制本发明内容,仅表示本次发明选定的实施例。熟悉本发明的技术人员,可利用上述阐述的技术内容加以改变成为等同效实施例。
Claims (10)
1.一种阻断新型冠状病毒2019-nCov的无菌喷剂敷料的应用,其特征在于,所述无菌喷剂敷料含有生物活性肽LHT和辅料,其中,生物活性肽LHT添加量0.1%-0.5%,辅料含有增稠剂0.1%-1%,防腐剂0.01%-0.5%,柠檬酸0.01%-0.2%,氯化钠0.3%-0.9%、磷酸氢二钠0.1%-1.5%,乙二胺四乙酸二钠0.01%-0.06%,纯化水适量,所述增稠剂优选羟乙基纤维素、羧甲基纤维素钠中的一种,所述防腐剂优选羟苯甲酯、羟苯甲酯钠、羟苯乙酯中的一种或几种。
2.根据权利要求1所述无菌喷剂敷料的应用,其特征在于,所述无菌喷剂敷料所含的生物活性肽LHT来源于海洋微藻裂殖壶菌酶解活性肽及驴血清蛋白质酶解混合物。
3.根据权利要求1-2所述无菌喷剂敷料的应用,其特征在于,所述无菌喷剂敷料所含的生物活性肽LHT的含有的氨基酸有丙氨酸(Ala),精氨酸(Arg),天门冬氨酸(Asp),谷氨酸(Glu),甘氨酸(Gly),组氨酸(His),异亮氨酸(Ile),亮氨酸(Leu),赖氨酸(Lys),脯氨酸(Pro),丝氨酸(Ser),苏氨酸(Thr),色氨酸(Trp),酪氨酸(Tyr),缬氨酸(Val),天门冬酰胺(Asn),半胱氨酸(Cys)。
4.根据权利要求1-3所述无菌喷剂敷料的应用,其特征在于,所述无菌喷剂敷料所含的生物活性肽LHT的含有生物活性肽的分子式为 C43H76N10O18,C29H47N6O9,C33H60N7O9,C28H49N6O8S。
5.根据权利要求1-4所述无菌喷剂敷料的应用,其特征在于,所述无菌喷剂敷料应用于II、III 类医疗器械产品。
6.根据权利要求1-5所述无菌喷剂敷料的应用,其特征在于,所述无菌喷剂敷料用于口腔或鼻腔。
7.根据权利要求1-6所述无菌喷剂敷料的应用,其特征在于,所述无菌喷剂敷料主要成分生物活性肽LHT还可以与病毒结合,钝化病毒,屏障病毒于人体外。
8.根据权利要求7所述无菌喷剂敷料的应用,其特征在于,所述无菌喷剂敷料主要成分生物活性肽LHT喷入到鼻腔或者口腔后,形成一道保护层,当病毒接触到鼻腔或者口腔的这层保护层后,生物活性肽LHT迅速和病毒的衣壳M蛋白质结合,使得其在未接触人体细胞之前就被挡在体外。
9.根据权利要求1-6所述无菌喷剂敷料的应用,其特征在于,所述无菌喷剂敷料主要成分生物活性肽LHT能与病毒衣壳蛋白质竞争结合人体表皮细胞膜外的蛋白质,阻断病毒侵入人体细胞的途径。
10.根据权利要求9所述无菌喷剂敷料的应用,其特征在于,所述无菌喷剂敷料主要成分生物活性肽LHT喷入到鼻腔或者口腔后,可与人体表皮细胞膜上的血管紧张素转换酶ACE及ACE2蛋白酶裸露外部的部位结合,使得新型冠状病毒入侵细胞的途径被阻断。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010086854.1A CN111012736A (zh) | 2020-02-11 | 2020-02-11 | 一种阻断新型冠状病毒2019-nCov的无菌喷剂敷料的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010086854.1A CN111012736A (zh) | 2020-02-11 | 2020-02-11 | 一种阻断新型冠状病毒2019-nCov的无菌喷剂敷料的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111012736A true CN111012736A (zh) | 2020-04-17 |
Family
ID=70203418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010086854.1A Pending CN111012736A (zh) | 2020-02-11 | 2020-02-11 | 一种阻断新型冠状病毒2019-nCov的无菌喷剂敷料的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111012736A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111474350A (zh) * | 2020-04-23 | 2020-07-31 | 中国林业科学研究院林业研究所 | 一种检测冠状病毒s1抗原的试剂盒及其非诊断目的的检测方法 |
IT202100016037A1 (it) * | 2021-06-18 | 2021-09-18 | Antonio Bianchi | Formulazione spray per uso nasale/orale con attivita’ contro i coronavirus respiratori |
WO2022084931A1 (en) * | 2020-10-23 | 2022-04-28 | Antonio Bianchi | Spray formulation for nasal/oral use with activity against respiratory coronaviruses and in particular the sars-cov-2 virus |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110195449A1 (en) * | 2009-12-28 | 2011-08-11 | Martek Biosciences Corporation | Recombinant Thraustochytrids that Grow on Sucrose, and Compositions, Methods of Making, and Uses Thereof |
CN105555290A (zh) * | 2013-05-10 | 2016-05-04 | 莱顿大学学术医院以Lumc的名义运作 | 抗微生物肽 |
CN106755229A (zh) * | 2016-11-24 | 2017-05-31 | 福州大学 | 一种裂殖壶菌藻粕蛋白酶解肽的制备方法 |
WO2017197542A1 (zh) * | 2016-05-20 | 2017-11-23 | 浙江红雨医药用品有限公司 | 一种抑菌敷料及其制备方法与应用 |
-
2020
- 2020-02-11 CN CN202010086854.1A patent/CN111012736A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110195449A1 (en) * | 2009-12-28 | 2011-08-11 | Martek Biosciences Corporation | Recombinant Thraustochytrids that Grow on Sucrose, and Compositions, Methods of Making, and Uses Thereof |
CN105555290A (zh) * | 2013-05-10 | 2016-05-04 | 莱顿大学学术医院以Lumc的名义运作 | 抗微生物肽 |
WO2017197542A1 (zh) * | 2016-05-20 | 2017-11-23 | 浙江红雨医药用品有限公司 | 一种抑菌敷料及其制备方法与应用 |
CN106755229A (zh) * | 2016-11-24 | 2017-05-31 | 福州大学 | 一种裂殖壶菌藻粕蛋白酶解肽的制备方法 |
Non-Patent Citations (4)
Title |
---|
GEETANJALI MEHER,等: "Membrane Cholesterol Modulates Oligomeric Status and Peptide-Membrane Interaction of Severe Acute Respiratory Syndrome Coronavirus Fusion Peptide", 《J. PHYS. CHEM. B》 * |
崔春: "《食物蛋白质控制酶解技术》", 30 June 2018, 中国轻工业出版社 * |
李青叶: "驴血清蛋白酶解物生产工艺的优化及活性初步研究", 《中国优秀博硕士学位论文全文数据库(硕士) 工程科技Ⅰ辑》 * |
梁双振: "源于海洋微藻生物活性肽的研究", 《中国优秀博硕士学位论文全文数据库(硕士) 基础科学辑》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111474350A (zh) * | 2020-04-23 | 2020-07-31 | 中国林业科学研究院林业研究所 | 一种检测冠状病毒s1抗原的试剂盒及其非诊断目的的检测方法 |
CN111474350B (zh) * | 2020-04-23 | 2023-07-07 | 中国林业科学研究院林业研究所 | 一种检测冠状病毒s1抗原的试剂盒及其非诊断目的的检测方法 |
WO2022084931A1 (en) * | 2020-10-23 | 2022-04-28 | Antonio Bianchi | Spray formulation for nasal/oral use with activity against respiratory coronaviruses and in particular the sars-cov-2 virus |
IT202100016037A1 (it) * | 2021-06-18 | 2021-09-18 | Antonio Bianchi | Formulazione spray per uso nasale/orale con attivita’ contro i coronavirus respiratori |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111012736A (zh) | 一种阻断新型冠状病毒2019-nCov的无菌喷剂敷料的应用 | |
DK180405B1 (en) | Novel trypsin isoforms and their use | |
Siniavin et al. | Snake venom phospholipase A2s exhibit strong virucidal activity against SARS-CoV-2 and inhibit the viral spike glycoprotein interaction with ACE2 | |
JP2021509809A (ja) | コロナウイルス感染症の治療または予防に使用するためのプロテアーゼ活性を有するペプチド | |
CN111728963A (zh) | 葡萄糖酸铜在制备用于预防或治疗新型冠状病毒感染的药物中的应用 | |
EP4146245A1 (en) | Mannose-binding lectin for treatment or prophylaxis of infectious diseases | |
Li et al. | SARS-CoV-2 and emerging variants: unmasking structure, function, infection, and immune escape mechanisms | |
US20200276262A1 (en) | Peptides for use in the treatment of viral infections | |
Pineda et al. | Quinacrine as a potential treatment for COVID-19 virus infection. | |
JPH06507386A (ja) | 治療用ペプチド | |
EP4138891A1 (en) | Peptides for the treatment of covid-19 | |
EP4147702A1 (en) | Novel combination of heparin and ace2 decoys for the treatment of covid-19 | |
US11376306B2 (en) | Peptides and uses therefor as antiviral agents | |
US5900401A (en) | Remedy for respiratory-tract viral disease | |
US20240000901A1 (en) | Use of polypeptide having superoxide dismutase activity and extracellular vesicles for treatment or prevention of respiratory viral infection | |
WO2011110861A2 (en) | Therapy for influenza like illness | |
Kobayashi-Sakamoto et al. | Lactoferrin as a Possible Preventive and Therapeutic Agent Against SARS-CoV-2 Infection | |
Priadharsini et al. | Lung Recruitability in COVID-19 | |
WO2022207918A1 (en) | COVID-19 Therapy | |
Tavakoli et al. | Oral symptoms of patients tested positive for COVID-19 with mild severity-a cross-sectional study | |
MXPA96004207A (en) | Novedous remedy for tractor pyrrato viral disease | |
CN104311644A (zh) | 多肽、提高多肽稳定性的方法、药物组合物以及多肽在制备药物中的用途 | |
TW202334430A (zh) | 自酵母菌產生之alpha-1抗胰蛋白酶用於治療病毒感染 | |
EP4331571A1 (en) | Formulations of ace2-igm fusion proteins | |
JP2023006351A (ja) | 抗ウイルス用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200417 |
|
WD01 | Invention patent application deemed withdrawn after publication |